Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Craig M. Crews

Arvinas, Inc.

Eilean Therapeutics is a small molecule oncology drug discovery company that develops pan-variant therapies for hematologic malignancies targeting major drivers of cancer resistance.

Eilean Therapeutics

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.Community Guidelines: http://bit.ly/ArvinasCG

Metric
Company Name	Arvinas, Inc.	Eilean Therapeutics
Symbol	ARVN
MSH ID	COM:ARVINAS	COM:EILEANTHER
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	445
Website	arvinas.com	eileanther.com
LinkedIn	arvinas
Founders

Metric
Market Cap	1.80B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	78.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	71.80M
EBITDA	-394.80M
Operating Income	-401.50M
Net Income	-367.30M
EPS	-6.62
Diluted EPS	-6.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.95
Operating Profit Margin	-3.98
EBITDA Margin	-5.03
Net Profit Margin	-3.47
Return on Equity	-0.56
Return on Assets	-0.25
Return on Capital Employed	-0.38

COM:ARVINAS

Arvinas, Inc.

Last Close

25.11

22/11 21:00

Market Cap

1.80B

Beta: -

Volume Today

1.04M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.65
P/B Ratio	5.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	37.00
EV Multiple	-4.38

Metric
Days Sales Outstanding	47.11
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	87.03
Cash Conversion Cycle	87.03
Asset Turnover	0.07

Metric
Operating Cash Flow	-347.80M
Free Cash Flow	-350.70M
Cash Flow to Debt	-102.43
Operating Cash Flow/Sales	-2.31
Free Cash Flow Yield	-0.13

Metric
Cash & Equivalents	317.20M
Accounts Receivable	800K
Inventory
Goodwill
Debt to Capitalization	0.00
Debt to Assets	0.00
Current Ratio	3.26
Quick Ratio	4.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.47
R&D to Revenue	2.40
SG&A to Revenue	0.55